Keep up with the fast pace of COVID-19 research with a series of concise “Science Spotlight” commentaries and audio podcasts featuring a pair of experts discussing the most clinically relevant new COVID-19 data.
Here are my thoughts on how developing data may help you assess immunocompromised patients’ risk of severe COVID-19 illness.
Navigating what is currently known about responsiveness to COVID-19 vaccines and the potential for SARS-CoV-2 variants in immunocompromised patients.
Neutralizing antibodies are an attractive strategy for prevention and treatment of COVID-19, particularly for unvaccinated persons and others at high risk of infection. Here’s my take on 2 exciting new studies in this field.
My take on the potential utility of casirivimab plus imdevimab for hospitalized patients with COVID-19 who have higher viral burden and delayed antibody responses.
In 2020, New York City was an epicenter of the COVID-19 pandemic, and race-related disparities in patients with COVID-19 presenting to our hospital were evident. Here’s my take on 4 new analyses showing that increased risk of COVID-19 illness and poorer outcomes reflect the preexisting, deep socioeconomic inequities that affect health and access to healthcare.
In this commentary, I review recent studies assessing the potential role for TDF in limiting SARS-CoV-2 replication.
What if one in 4 COVID-19 deaths during a surge could be avoided? My take on important new data showing that COVID-19 caseload surges adversely affect COVID-19 mortality rates.
Listen to Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss exciting new data on the use of monoclonal antibodies for the treatment and prevention of COVID-19.